Back

Improved efficacy and tolerability of antisense oligonucleotide with Guanidine- bridged nucleic acid

Tomita, H.; Kawanobe, T.; Shrestha, A. R.

2026-01-08 pharmacology and toxicology
10.64898/2026.01.08.698310 bioRxiv
Show abstract

Guanidine- bridged nucleic acid (GuNA) is a bridged nucleic acid analog with high binding affinity towards complementary strands along with high nuclease resistance. GuNA has been developed to improve pharmacokinetics and safety profiles of phosphorothioate modified gapmers. Here, we evaluated antisense oligonucleotides (ASOs) modified with combination of GuNA and 2-O-methoxyethyl (MOE) could significantly improve KD activity in vitro and in vivo. Long-term efficacy evaluation showed that intracerebroventricularly administered GuNA modified gapmers stayed active for over 24 weeks in mouse brain. Furthermore, we found that GuNA-modified gapmers could evade lymphocyte-derived immune responses and kept ASO-induced toxicity in check. Taken together, the results of this study demonstrated that GuNA modification can improve the potential of ASOs, especially in the central nervous system.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Molecular Therapy Nucleic Acids
○ 32 papers in training set
Top 0.1%
33.8%
2
PLOS ONE
● 4510 papers in training set
Top 30%
5.0%
3
Nucleic Acids Research
◐ 1128 papers in training set
Top 5%
3.8%
4
BioMed Research International
○ 25 papers in training set
Top 0.7%
3.7%
5
Clinical and Translational Medicine
○ 30 papers in training set
Top 0.1%
3.7%
6
ACS Omega
● 90 papers in training set
Top 0.4%
3.7%
50% of probability mass above
7
International Journal of Biological Macromolecules
○ 65 papers in training set
Top 0.6%
3.7%
8
Scientific Reports
○ 3102 papers in training set
Top 41%
3.1%
9
Molecular Therapy
○ 71 papers in training set
Top 1.0%
2.4%
10
ACS Chemical Neuroscience
● 60 papers in training set
Top 0.9%
2.1%
11
Frontiers in Pharmacology
○ 100 papers in training set
Top 2%
1.8%
12
Molecular Pharmaceutics
● 16 papers in training set
Top 0.3%
1.3%
13
Biomedicine & Pharmacotherapy
○ 43 papers in training set
Top 0.6%
1.3%
14
Molecular Therapy - Nucleic Acids
○ 24 papers in training set
Top 0.2%
1.1%
15
Journal of Translational Medicine
○ 46 papers in training set
Top 2%
1.1%
16
Cell Proliferation
○ 12 papers in training set
Top 0.3%
0.9%
17
ACS Biomaterials Science & Engineering
● 37 papers in training set
Top 0.9%
0.9%
18
Cells
○ 232 papers in training set
Top 5%
0.8%
19
The CRISPR Journal
○ 33 papers in training set
Top 0.3%
0.8%
20
Medicine
○ 30 papers in training set
Top 2%
0.8%
21
Clinical and Translational Science
○ 21 papers in training set
Top 1.0%
0.8%
22
Cell Reports Physical Science
○ 18 papers in training set
Top 0.7%
0.8%
23
Chemical Communications
● 24 papers in training set
Top 1%
0.8%
24
ChemBioChem
○ 50 papers in training set
Top 1%
0.8%
25
Frontiers in Genetics
○ 197 papers in training set
Top 9%
0.8%
26
Biomedicines
○ 66 papers in training set
Top 3%
0.8%
27
ACS Sensors
● 45 papers in training set
Top 1%
0.8%
28
Cancer Medicine
○ 24 papers in training set
Top 1%
0.7%
29
International Journal of Molecular Sciences
○ 453 papers in training set
Top 19%
0.5%
30
Molecules
○ 37 papers in training set
Top 3%
0.5%